Thymomodulin as an Immunomodulatory Agent in Animal Species: a Scoping Review on Animal Health Impacts, One Health Interfaces, and Translational Relevance
Open Access
- 1 January 2026
- journal article
- review article
- Published by FapUNIFESP (SciELO) in Brazilian Archives of Biology and Technology
- Vol. 69
Abstract
Thymomodulin is a thymus-derived peptide preparation with immunomodulatory properties studied in experimental and veterinary contexts. Within a One Health framework, integrating animal, human, and environmental health, enhancing animal immunity is hypothesized to aid disease prevention, reduce zoonotic transmission, and decrease antimicrobial use. This scoping review mapped evidence on thymomodulin and comparable calf thymus extracts as immunomodulators in non-human animals from 2000 to 2025, evaluating their relevance for One Health strategies. A structured literature search (1 January 2000-31 December 2025) was conducted in PubMed, Scopus, Web of Science, and SciELO, supplemented by grey literature and patent searches. Peer-reviewed studies reporting immunological or clinical outcomes in non-human animals were included; human-only studies and those lacking immune or health endpoints were excluded. Across species, thymomodulin consistently modulated innate and adaptive immunity. In fish, dietary supplementation enhanced vaccine responsiveness, antibody titers, and survival after pathogen challenge. In rodents, thymomodulin restored immune function in immunosuppressed models and accelerated pathogen clearance. In companion animals, adjunct therapy improved clinical outcomes, including increased survival and faster remission in cats with disseminated sporotrichosis, as well as improved hematological parameters in immunocompromised animals. Evidence from poultry and swine suggests enhanced vaccine-induced immunity and maternal transfer of immune protection. Overall, thymomodulin acts as an immune normalizer, reinforcing host defenses under immune compromise. These immunological benefits could potentially reduce pathogen shedding and the need for antimicrobials indirectly; however, the evidence remains heterogeneous. Standardized clinical trials and field-based studies are needed to support translation into One Health practice.Keywords
Funding Information
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (406436/2022-3)
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (310806/2025-9)
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (119870/2025-8)
This publication has 16 references indexed in Scilit:
- Advances in soft nanoparticle-based platforms for human and veterinary trichomoniasis therapy: A scoping reviewEuropean Journal of Pharmaceutics and Biopharmaceutics, 2025
- Thymomodulin in association with antifungal drugs in the therapy of cats with disseminated cutaneous sporotrichosis: a prospective studyCiência Rural, 2021
- Updated methodological guidance for the conduct of scoping reviewsJBI Evidence Synthesis, 2020
- Saccharomyces uvarum mannoproteins stimulate a humoral immune response in miceBrazilian Archives of Biology and Technology, 2012
- Synergic interaction between ascorbic acid and antibiotics against Pseudomonas aeruginosaBrazilian Archives of Biology and Technology, 2005
- Compartmentalisation between Gut and Lung Mucosae in a Model of Secondary Immunodeficiency: Effect of ThymomodulinInternational Journal of Immunopathology and Pharmacology, 2003
- The influence of nonspecific immunostimulation of pregnant sows on the immunological value of colostrumVeterinary Immunology and Immunopathology, 2002
- Thymomodulin Stimulates PhagocytosisIn Vitroby Rat Macrophages and Human Polymorphonuclear CellsJournal of Chemotherapy, 1993
- ImmunostimulantsImmunology Today, 1993
- Thymomodulin: biological properties and clinical applicationsMedical Oncology and Tumor Pharmacotherapy, 1989